JCR Pharmaceuticals Co., Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JCRRF research report →
Price Chart
About the company
JCR Pharmaceuticals Co. , Ltd. , a specialized pharmaceutical company headquartered in Ashiya, Japan, and established in 1975, operates across the entire lifecycle of pharmaceutical products, regenerative medicines, and active drug substances.
- CEO
- Toru Ashida
- IPO
- 2021
- Employees
- 985
- HQ
- Ashiya, HY, JP
Get TickerSpark's AI analysis on JCRRF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $405.10M
- P/E
- 78.72
- Fwd P/E
- 0.84
- PEG
- 1.21
- P/S
- 1.56
- P/B
- 1.49
- EV/EBITDA
- 24.04
- Div Yield
- 3.78%
- Gross Margin
- 75.60%
- Op Margin
- -2.48%
- Net Margin
- 1.97%
- ROE
- 1.77%
- ROIC
- -0.47%
Latest fiscal year · YoY change
- Revenue
- $40.57B+22.7%
- Gross Profit
- $30.25B+39.2%
- Op Income
- $433.71M
- Net Income
- $2.19B+146.1%
- EPS
- $17.58+145.7%
- OCF Growth
- +97.5%
- FCF Growth
- +24.3%
- 52W High
- $5.00
- 52W Low
- $3.15
- 50D MA
- $3.26
- 200D MA
- $4.03
- Beta
- 0.53
- RSI (14)
- 53
- Avg Volume
- 34
No earnings-call transcripts are available for JCRRF yet.
- Free Float
- 56.9%
- Shares Outstanding
- 122.02M
- Float Shares
- 69.44M
Our JCRRF coverage
Recent articles, reports, and earnings notes.
No research on JCRRF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate JCRRF report →JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome
businesswire.com · Jul 21
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform
businesswire.com · Jun 17
JCR Pharmaceuticals' Research Presentations at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders
businesswire.com · Jun 8
JCR Pharmaceuticals to Present at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026
businesswire.com · May 28
JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising Central Nervous System Uptake at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
businesswire.com · May 18
JCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
businesswire.com · May 11
JCR Pharmaceuticals' Research Presentations at WORLDSymposium™ 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders
businesswire.com · Feb 4
JCR Pharmaceuticals to Present at the 22nd Annual WORLDSymposium™ 2026
businesswire.com · Jan 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.